Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Befetupitant (Ro67-5930) 是一种具有有效性和选择性的速激肽 1 受体 (NK1R) 拮抗剂,可用于研究角膜新生血管形成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,500 | 现货 | ||
5 mg | ¥ 7,700 | 现货 | ||
10 mg | ¥ 9,800 | 现货 | ||
25 mg | ¥ 12,000 | 现货 | ||
50 mg | ¥ 15,300 | 现货 | ||
100 mg | ¥ 19,500 | 现货 |
产品描述 | Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization. |
体内活性 | In the alkali burn model, Befetupitant, a highly selective NK1R antagonist, was tested. Hemangiogenesis and lymphangiogenesis were effectively reduced (P<0.05) after topical application of Befetupitant for 4 days at both concentrations (0.4 and 1.6 mg/mL). However, both Befetupitant and its vehicle DMSO induced corneal opacity even in healthy controls, as observed during slit-lamp examination. Furthermore, fluorescein and hematoxylin-eosin staining confirmed DMSO toxicity by revealing epithelial damage and inflammatory cellular infiltration in the stroma. Despite Befetupitant's effectiveness in reducing corneal neovascularization (CNV) in the alkali burn model, its toxicity due to the DMSO vehicle led to the decision not to test it in the suture model[1]. |
别名 | Ro67-5930 |
分子量 | 565.55 |
分子式 | C29H29F6N3O2 |
CAS No. | 290296-68-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Befetupitant 290296-68-3 Neuroscience GPCR/G Protein Neurokinin receptor Ro67-5930 Inhibitor inhibitor inhibit